中国医师协会泌尿外科医师分会肾上腺性高血压外科协作组 ;中华医学会内分泌学分会肾上腺学组 ;中华医学会核医学分会 PET 学组;
Chinese Urological Doctor Association Adrenal Hypertension Surgery Collaborative Organization ;Adrenal Group,Chinese Society of Endocrinology ;PET group,Chinese Society of Nuclear Medicine;

摘要(Abstract)：

原发性醛固酮增多症的分型诊断是临床工作的重点和难点，越来越多的临床证据表明，靶向CXCR4的⁽⁶⁸⁾Ga-Pentixafor PET/CT核素显像可辅助原发性醛固酮增多症的分型。基于国内外最新研究证据，经多学科专家组深入讨论，在核素显像方法和结果判读，以及其对治疗方案的指导和预后评估方面达成了一致意见。本共识为规范国内(68)Ga-Pentixafor PET/CT核素显像可辅助原发性醛固酮增多症的分型。基于国内外最新研究证据，经多学科专家组深入讨论，在核素显像方法和结果判读，以及其对治疗方案的指导和预后评估方面达成了一致意见。本共识为规范国内⁽⁶⁸⁾Ga-Pentixafor PET/CT显像，提高我国原发性醛固酮增多症诊疗水平提供了重要依据。
Subtype classification of primary aldosteronism is important but challenging. Increasing evidence has shown that (68)Ga-Pentixafor PET/CT显像，提高我国原发性醛固酮增多症诊疗水平提供了重要依据。
Subtype classification of primary aldosteronism is important but challenging. Increasing evidence has shown that ⁽⁶⁸⁾Ga-Pentixafor PET/CT imaging which targets CXCR4 is beneficial to the subtype classification of primary aldosteronism. Based on all the available evidence, and after in-depth discussion of a group of multi-disciplinary experts, a consensus has been established, which covers imaging technology, interpretation of results of CXCR4 imaging, and the guidance to the choice of the treatment and prognosisevaluation. The consensus is helpful for standardizing (68)Ga-Pentixafor PET/CT imaging which targets CXCR4 is beneficial to the subtype classification of primary aldosteronism. Based on all the available evidence, and after in-depth discussion of a group of multi-disciplinary experts, a consensus has been established, which covers imaging technology, interpretation of results of CXCR4 imaging, and the guidance to the choice of the treatment and prognosisevaluation. The consensus is helpful for standardizing ⁽⁶⁸⁾Ga-Pentixafor PET/CT imaging and promoting a better diagnosis procedure in primary aldosteronism.

关键词(KeyWords)： 原发性醛固酮增多症;CXCR4受体;~(68)Ga-Pentixafor PET/CT;专家共识
primary aldosteronism;CXCR4 receptor;~(68)Ga-Pentixafor PET/CT;expert consensus

Abstract:

Keywords:

基金项目(Foundation): 中央高水平医院临床科研业务费(2022-PUMCH-C-028,2022-PUMCH-B-010);; 中国医学科学院创新工程(2022-I2M-JB-001)~~

作者(Authors): 中国医师协会泌尿外科医师分会肾上腺性高血压外科协作组 ;中华医学会内分泌学分会肾上腺学组 ;中华医学会核医学分会 PET 学组;
Chinese Urological Doctor Association Adrenal Hypertension Surgery Collaborative Organization ;Adrenal Group,Chinese Society of Endocrinology ;PET group,Chinese Society of Nuclear Medicine;

参考文献(References)：

• [1] Funder JW,Carey RM,Mantero F,et al.The Management of Primary Aldosteronism:Case Detection,Diagnosis,and Treatment:An Endocrine Society Clinical Practice Guideline[J].J Clin Endocrinol Metab,2016,101:1889- 1916.
• [2] Mulatero P,Monticone S,Deinum J,et al.Genetics,prevalence,screening and confirmation of primary aldosteronism:a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension[J].J Hypertens,2020,38:1919- 1928.
• [3] Wang H,Wang F,Zhang Y,et al.Surgical Outcomes of Aldosterone-Producing Adenoma on the Basis of the Histopathological Findings[J].Front Endocrinol (Lausanne),2021,12:663096.
• [4] Mulatero P,Sechi LA,Williams T A,et al.Subtype diagnosis,treatment,complications and outcomes of primary aldosteronism and future direction of research:a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension[J].J Hypertens,2020,38:1929- 1936.
• [5] Walenkamp A,Lapa C,Herrmann K,et al.CXCR4 Ligands:The Next Big Hit?[J].J Nucl Med,2017,58:77S- 82S.
• [6] Heinze B,Fuss CT,Mulatero P,et al.Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma[J].Hypertension,2018,71:317- 325.
• [7] Ding J,Zhang Y,Wen J,et al.Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism[J].Eur J Nucl Med Mol Imaging,2020,47:2656- 2665.
• [8] Ding J,Tong A,Zhang Y,et al.Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using (68)Ga-Pentixafor[J].J Nucl Med,2022,63:368- 375.
• [9] Ding J,Tong A,Zhang Y,et al.Intense 68Ga-Pentixafor Activity in Aldosterone-Producing Adrenal Adenomas[J].Clin Nucl Med,2020,45:336- 339.
• [10] Gao Y,Ding J,Cui Y,et al.Functional nodules in primary aldosteronism:identification of CXCR4 expression with (68)Ga-Pentixafor PET/CT[J].Eur Radiol,2022.doi:10.1007/s00330- 022- 09058-x.
• [11] Song Y,Yang J,Shen H,et al.Development and validation of model for sparing adrenal venous sampling in diagnosing unilateral primary aldosteronism[J].J Hypertens,2022,40:1692- 1701.
• [12] Fu B,Zhang X,Wang GX,et al.Long-term results of a prospective,randomized trial comparing retroperitoneoscopic partial versus total adrenalectomy for aldosterone producing adenoma[J].J Urol,2011,185:1578- 1582.
• [13] 中华医学会内分泌学分会.原发性醛固酮增多症诊断治疗的专家共识(2020版)[J].中华内分泌代谢杂志，2020,36:727- 736.Chinese Society of Endocrinology.Expert consensus on the diagnosis and treatment of primary aldosteronism (2020) [J].Zhonghua Neifenmi Daixie Zazhi,2020,36:727- 736.
• [14] Steichen O,Zinzindohoué F,Plouin PF,et al.Outcomes of adrenalectomy in patients with unilateral primary aldosteronism:a review[J].Horm Metab Res,2012,44:221- 227.
• [15] Williams TA,Lenders JWM,Mulatero P,et al.Outcomes after adrenalectomy for unilateral primary aldosteronism:an international consensus on outcome measures and analysis of remission rates in an international cohort[J].Lancet Diabetes Endocrinol,2017,5:689- 699.